Loading financials from SEC filings…
Biotechnology · Healthcare · Fiscal year ends Mar 31
Net income was −$506M. Operating cash flow of −$407M less capital expenditure of $8,000 left free cash flow of −$407M.
Last 5 fiscal years
| Fiscal year | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Research & development | 102 | 160 | 213 | 361 | 457 |
| Net interest incomeBanks | 0.0 | 7.6 | 24.9 | – | – |
| Pre-tax income | −157 | −211 | −259 | −413 | −505 |
| Income tax | −0.1 | 0.0 | 0.6 | 0.9 | 0.2 |
| Net income | −157 | −211 | −259 | −414 | −506 |
| Diluted EPS | −1.43 | −1.71 | −1.88 | −2.73 | −2.77 |
| Diluted shares | 110 | 123 | 138 | 152 | 182 |
| Fiscal year | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Cash & equivalents | 494 | 377 | 635 | 714 | 902 |
| Receivables | 12.2 | 0.7 | 5.3 | 2.1 | 1.1 |
| Current assets | 513 | 404 | 666 | 768 | 949 |
| Net PP&E | 0.3 | 0.3 | 0.5 | 0.8 | 0.4 |
| Total assets | 516 | 406 | 666 | 776 | 957 |
| Payables | 18.6 | 1.4 | 7.2 | 17.7 | 7.5 |
| Current liabilities | 44.5 | 43.3 | 48.6 | 68.8 | 104 |
| Total liabilities | 45.7 | 43.3 | 48.6 | 68.8 | 104 |
| Shareholders' equity | 470 | 362 | 618 | 707 | 853 |
| Fiscal year | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating cash flow | −106 | −188 | −214 | −376 | −407 |
| Capital expenditure | 0.3 | 0.2 | 0.4 | 0.8 | 0.0 |
| Free cash flow | −106 | −188 | −215 | −377 | −407 |
| Depreciation & amortisation | 0.1 | 0.2 | 0.2 | 0.4 | 0.4 |
| Stock-based compensation | 34.2 | 32.3 | 41.1 | 49.5 | 55.7 |
| Fiscal year | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Return on equityBlank when equity is negative | −33.4% | −58.2% | −42.0% | −58.5% | −59.3% |
| Cash conversion (CFO ÷ net income) | 0.68x | 0.89x | 0.83x | 0.91x | 0.81x |
| Current ratio | 11.5x | 9.34x | 13.7x | 11.2x | 9.09x |
Standardised figures from the company's XBRL filings with the SEC (10-K, 10-Q). Line items follow US GAAP tags, so a company's own statement layout may differ and some lines show “–” where the company does not report that item. Ratios are calculated from these figures. For education only; not investment advice or a recommendation.